Metabolic Biomarkers Indicate Exposure to Gamma Radiation
Description of Invention:
Available for licensing and commercial development are methods of diagnosing exposure to gamma radiation in a mammal. Gamma radiation has both short-term and long-term adverse health effects including cancer. Urine samples collected from exposed mouse models irradiated at 0, 3, and 8 Gy (2.57 Gy/min) were analyzed by ultra-performance liquid chromatography-time of flight mass spectrometry (UPLC-TOFMS). Statistical analysis revealed that the following metabolomic markers were associated with exposure: 2'-deoxyxanthosine, xanthosine, 2'-deoxyuridine, 2'-deoxycytidine, N-hexanoylglycine and P-thymidine are urinary biomarkers of 3 and 8 Gy exposure. 3-hydroxy-2-methylbenzoic acid 3-O-sulfate and xanthine are elevated in urine of mice exposed to 3 but not 8 Gy, and taurine is elevated after 8 but not 3 Gy exposure.
Applications:
Radiation exposure
Metabolomics
Inventors: Frank J. Gonzalez (NCI) John Tyburski (NCI) Kristopher Krausz (NCI) Andrew Patterson (NIGMS) et al.
Patent Status:
DHHS Reference No. E-070-2008/0 --
U.S. Patent Application No. 12/121,208 filed 15 May 2008
Relevant Publication:
Patterson AD, Li H, Eichler GS, Krausz KW, Weinstein JN, Fornace AJ, Gonzalez FJ, Idle JR. UPLC-ESI-TOFMS-based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. Anal Chem. 2008 Feb 1;80(3):665-674. [PubMed abs]
Tyburski JB, Patterson AJ, Krausz KW, Slavík J, Fornace AJ, Gonzalez FJ, Idle JR. Radiation metabolomics: 1. Identification of minimally invasive urine biomarkers for gamma radiation exposure in mice. Radiat Res. 2008 Jul;170(1):1-14. [PubMed abs]
Licensing Status: Available for licensing
Collaborative Research Opportunity:
The National Cancer Institute, Laboratory of Metabolism, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the development of biomarkers for radiation gamma exposure and cell damage. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
Portfolios: Internal Medicine Devices/Instrumentation
For Additional Information Please Contact: Michael Shmilovich J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5019
Email: shmilovm@mail.nih.gov
Fax: (301) 402-0220
